TMPRSS2-ERG gene fusion leading to the androgenic induction of the ERG proto-oncogene expression is a highly prevalent oncogenic alteration in prostate tumor cells. Prostate cancer is a multi-focal disease, and the origins as well as biological contribution of multiple cancer foci remain unclear with respect to prostate cancer onset or progression. To assess the role of TMPRSS2-ERG alteration in prostate cancer onset and/or progression, we have evaluated the status of fusion transcripts in benign glands, prostatic intraepithelial neoplasia (PIN) and multiple cancer foci of each prostate. Quantitative expression of TMPRSS2-ERG fusion type A and C transcripts was analyzed in benign, tumor and PIN areas, selected from whole-mount radical prostatectomy slides. TMPRSS2-ERG expression was correlated with clinicopathological features. Overall, 30 of 45 (67%) patients exhibited TMPRSS2-ERG fusion transcripts in at least one tumor focus. Of 80 tumor foci analyzed, 39 had TMPRSS2-ERG fusion (type A only: 30, type C only: 2, both types A and C: 7), with predominant detection of the TMPRSS2-ERG fusion type A (27/30, 90%) in the index tumors. Of 14 PIN lesions, 2 were positive for type A fusion. Frequent presence of the TMPRSS2-ERG in index tumors suggests critical roles of ERG alterations in the onset and progression of a large subset of prostate cancer. However, heterogeneity of the TMPRSS2-ERG detection in the context of multiple cancer foci and its frequency in PIN also support the role of other genomic alterations in the origins of prostate cancer.
Prostate cancer has been recognized as a multi-focal disease. [1] [2] [3] Currently, in our series of over 1150 radical prostatectomies most specimens contain two or more independent tumors. It is still unclear whether each of these cancer foci contributes to patient's prognosis after the radical prostatectomy. We and others found that the larger tumors typically contain poorly differentiated foci.
1,2 Stamey et al 4 reported that percent Gleason grade 4/5, cancer volume of the largest tumor, positive lymph node findings and intraprostatic vascular invasion have been independently associated with prostate cancer progression.
Intertumoral as well as intratumoral heterogeneity with respect to genomic alterations has also been noted in multiple foci. 5 The biological significance of multiple independent foci of prostate cancer, histological grade heterogeneity within each tumor focus and difference in the anatomical location of the tumor are still unclear.
Recent reports of prevalent chromosomal rearrangements/translocations, leading to the activation of ETS transcription factors (predominantly ERG) through androgen receptor-inducible TMPRSS2 gene promoter, 6 underscore the critical role of ERG overexpression in prostate cancer. 7 Subsequent reports, [8] [9] [10] [11] [12] including our study, 13 have shown high frequency of TMPRSS2-ERG fusion and/or overexpression in clinically localized prostate cancers.
TMPRSS2 encodes an androgen-dependent transmembrane serine protease, which is strongly expressed in both normal tissue and prostate cancer. ETS transcription factors regulate the expression of genes with important cancer-relevant biological processes, such as cell growth, differentiation, and transformation.
14 TMPRSS2-ERG fusion may lead to prostate cancer cell-associated androgenic regulation of ERG 6 in prostate cancer cells. However, the biologic role of ERG overexpression in prostate cancer development and progression remains to be defined. Since TMPRSS2-ERG fusions lead to frequent alterations (460%) of the ERG protooncogene in early-stage prostate cancer, their evaluation in preneoplastic cells as well as multi-focal lesions from the same patient has potential to define its role in the prostate cancer onset, progression, and heterogeneity. This study analyzes TMPRSS2-ERG alterations in prostatic intraepithelial neoplasia (PIN) and multi-focal cancers sampled from wholemount prostate glands of prostate cancer patients.
Materials and methods

Cell Culture
Human prostate cancer cell line VCaP (cat. no. CRL-2876; American Type Culture Collection, Rockville, MD, USA) with known TMPRSS2-ERG fusion was grown in Dulbecco's modified Eagle's medium containing 4 mM L-glutamine, 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, and 10% fetal bovine serum. VCaP cells were used as positive control for TMPRSS2-ERG fusion expression and were also used for determining the sensitivity of detecting TMPRSS2-ERG fusion.
TMPRSS2-ERG Fusion Measurements in Formalin-Fixed Paraffin-Embedded VCaP Cells
To develop a set of positive controls for TMPRSS2-ERG fusion assessment in tissue sections, VCaP cell pellets were fixed with formalin and processed as paraffin blocks. A paraffin block containing VCaP cells was sectioned and utilized for checking the sensitivity and reproducibility of TMPRSS2-ERG fusion in formalin-fixed paraffin-embedded (FFPE) material. We determined that a minimum of 100 pg of VCaP RNA was needed for a reproducible realtime RT-PCR-based TMPRSS2-ERG fusion detection assay. PCR primers and PCR conditions are given in the Quantitative real-time RT-PCR section below.
Whole-Mount FFPE-Prostate Specimens and Correlation of TMPRSS2-ERG Expression with Clinicopathological Data
This study was performed under IRB-approved protocols (WU no. 04-28030, and WU no. 04-2871-98k). Prostatectomy specimens from patients treated at Walter Reed Army Medical Center were sectioned and embedded as whole mounts at the Armed Forces Institute of Pathology. After surgery, radical prostatectomy specimens were immediately fixed in 10% buffered formalin and embedded as whole mounts in paraffin. Each prostate was sectioned at 0.22 cm intervals in a transverse plane perpendicular to the long axis of the posterior surface of the prostate and completely embedded as whole mounts. The volume of each tumor was calculated in three dimensions (apex to base, right to left, and anterior to posterior) using the largest dimension in each direction. The volume did not include the shrinkage factor to correct for fixation and embedding. The tumor volumes of the measurable foci, from the largest (T1) to the smallest (T4) were recorded as T1-T4. The tumor dimension was not corrected for the actual tumor shape of the crosssection and, therefore, does not represent the true size of the tumor in cross-sectional area.
One 4-mm whole-mount slide was stained with hematoxylin and eosin, and used for a control. The adjacent two 6-mm sections were used for tissue dissection. Quantitative expression of the TMPRSS2-ERG was analyzed for a relationship with patient age at the time of surgery, race, clinical stage, preoperative PSA, prostatectomy pathology data (specimen size, tumor volume, grade, stage, and surgical margin status), and follow-up PSA data.
Definition of Non-Malignant Tissue and PIN
Epithelium was classified as histologically nonmalignant when glands contained two cell layers: the luminal cells with inconspicuous nucleoli and basal cells. Native glands were classified as PIN, when the secretory cells showed nuclear anaplasia and basal cells were detectable. 15 PIN adjacent to carcinoma (PIN located within 2 mm distance from the edge of tumor foci) and PIN distant from carcinoma (PIN located more than 2 mm distant from edge of tumor foci) were also evaluated for TMPRSS2-ERG fusion.
Tissue Micro-Dissections
Unstained 6-mm-thick tissue sections on glass slides were deparaffinized once with citrasolve buffer (cat. no. 22-143-975; Fisher Scientific, Pittsburgh, PA, USA) for 10 min, rinsed twice with 100% ethanol for 10 min, and air-dried. Specific histological fields of interest were selected (and ink marked) under the microscope by a genitourinary pathologist. Microdissection was performed using a pipette with an ultrafine pointed tip (cat. no. 2149p; Molecular BioProducts, San Diego, CA, USA). The histological area of interest on the tissue section was gently scraped with the pipette tip and RNA extraction buffer (total 250 ml RNA lysis buffer; 20 mM Tris (pH 7.4), 20 mM EDTA, 1% SDS, and 1 mg/ml proteinase K) until the selected cells became detached from the tissue section. Samples were transferred to Eppendorf tube and incubated overnight in 551C water bath. After incubation, 750 ml TRIzol (cat. no. 15596-026; Invitrogen, Carlsbad, CA, USA) was added into 
Results
The detailed topographical data of TMPRSS2-ERG fusion in multiple tumor foci of each patient are summarized in Table 1 . Representative wholemount prostate sections of six patients with TMPRSS2-ERG fusion transcript status are also shown in Figure 2 . Overall, 30 of 45 patients (67%) exhibited TMPRSS2-ERG fusion transcripts in at least one tumor focus. Heterogeneity of fusion transcripts in same patient specimen were apparent ( Figure 2 ). Of 80 tumor foci analyzed, 39 (49%) had TMPRSS2-ERG fusion. In these 39 fusion-positive tumor foci, 30 demonstrated the TMPRSS2-ERG fusion type A only, 2 showed TMPRSS2-ERG fusion type C only, and 7 had both types A and C. In PIN lesions, overall 2 of 14 foci were positive for fusion type A. In 5 of 14 cases, PIN was located adjacent to tumor (PIN located within 2 mm distance from edge of tumor foci) and 1 of these 5 foci was positive for TMPRSS2-ERG fusion type A. Among the PIN lesions distantly located (PIN located more than 2 mm distant from edge of tumor foci), 1 of 9 foci had TMPRSS2-ERG fusion type A.
Intriguingly, 2 of 45 RNA specimens from the benign prostatic glands also showed TMPRSS2-ERG fusion type A. These two cases were subjected to repeated pathological examination. However, based on morphology we could not identify malignancy in the areas sampled.
To determine whether the presence of TMPRSS2-ERG fusion type A in prostate cancer tissue was associated with disease progression, we compared PSA recurrence status between patients with or without fusion ( Table 2) . Among the 28 patients who had TMPRSS2-ERG fusion type A-positive tumors, 3 of 28 experienced PSA recurrence, whereas 4 of the 17 patients who had tumors without fusion transcript experienced PSA recurrence. There was no statistical difference between patients who had tumors with and without TMPRSS2-ERG fusion type A and PSA recurrence (P ¼ 0.3986). This was also confirmed by Kaplan-Meier unadjusted survival analysis, which did not show significance (P ¼ 0.42).
TMPRSS2-ERG fusions in multi-focal prostate cancer B Furusato et al
We also examined whether the presence of TMPRSS2-ERG fusion transcripts, especially TMPRSS2-ERG fusion type A, correlated with other prognostic variables. All the parameters, including age at diagnosis, race, preoperative PSA, clinical stage, pathological stage, Gleason score, surgical margin, prostate size, and index tumor volume, did not correlate with the presence of TMPRSS2-ERG fusion type A (Table 2) .
In a univariate Cox model, there was no relationship of the TMPRSS2-ERG fusion type A with various clinicopathologic variables; only Gleason score (P ¼ 0.0405) and index tumor volume (P ¼ 0.0132) were significant predictors for PSA recurrence (Table 3) .
In addition, we examined whether TMPRSS2-ERG fusion type A was frequently present in the index tumor by using Fisher exact test. For this analysis, a total of 27 prostatectomies were available, which contained at least both T1 (index or largest) and T2 (second largest) tumor in a given whole-mount section. TMPRSS2-ERG fusion type A was prevalent in 19 of 27 T1 compared to 8 of 27 T2. However, due to the small sample size, it was not statistically significant (P ¼ 0.36). 
TMPRSS2-ERG
fusions in multi-focal prostate cancer B Furusato et al
Discussion
Most prostates contain multi-focal tumors. 1, [16] [17] [18] [19] The heterogeneity of prostate cancer in multi-focal tumor context has also been well documented. The question arises whether these multi-focal tumors in the same prostate are of independent origin. To address this question, we analyzed the common genomic alterations of the TMPRSS2-ERG, recently described by several groups in clinically localized prostate cancer. 6, In the study by Gao et al, 13 at least one tumor focus of 67% of patients exhibited TMPRSS2-ERG fusion, of which is similar to our recent finding of 62% in laser capture microdissected OCT-embedded frozen specimens. We found that half of the specimens collected from the index tumor contained this molecular alteration. A  C  A  C  A  C  A  C  A  C  A  C  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45   N  PIN  T1  T2  T3  T4  Case No. Tumors T1, T2, T3, and T4 designate separate tumors in the same prostate. Red ¼ positive for TMPRSS2-ERG fusion; green ¼ negative for TMPRSS2-ERG fusion; gray ¼ not evaluable; A ¼TMPRSS2-ERG fusion type A; C ¼ TMPRSS2-ERG fusion type C; N ¼ non-malignant.
TMPRSS2-ERG
This study highlights the frequent presence of the TMPRSS2-ERG fusion transcripts in index tumors and suggests a critical role of ERG alterations in the onset and/or progression of a large subset of prostate cancer. TMPRSS2-ERG heterogeneity in separate tumor foci of the same patient further reinforces the concept of independent origin of multiple tumors, which had been addressed. 1, 42, 43 There was no statistical difference between patients who had tumors with and without TMPRSS2-ERG fusion type A and PSA recurrence (P ¼ 0.3986). The current data based on 45 patients show a similar trend as in our previous study based on frozen specimens. 13 However, the lack of prognostic significance of TMPRSS-ERG status may have been masked by the limited sample number.
Of 45 non-malignant samples, 2 showed TMPRSS2-ERG fusion. When these two cases were subjected to a repeated pathological examination, we could not identify PIN or carcinoma but some morphologically benign glands, some of which showed a-methylacylCoA racemase expression in luminal cells by immunohistochemistry. Previously, Leav et al 44 found that by using a-methylacyl-CoA racemase it is possible to define areas of transition from benign glands to malignant glands. Virtually, all of the TMPRSS2-ERG fusion reports show the gene fusion or the fusion transcripts in malignant glands. Figure 2 Topographical data of TMPRSS2-ERG fusion from six patients. Tumors T1, T2, and T3 designate separate tumors in the same prostate. PIN ¼ prostatic intraepithelial neoplasia; þ ¼ positive for TMPRSS2-ERG fusion; À ¼ negative for TMPRSS2-ERG fusion; A ¼TMPRSS2-ERG fusion type A; C ¼ TMPRSS2-ERG fusion type C.
TMPRSS2-ERG fusions in multi-focal prostate cancer B Furusato et al TMPRSS2-ERG fusion type A-positive benign glands may have the potential to develop into PIN or carcinoma. However, this hypothesis has to be further evaluated in a large cohort study.
We also found that a subset of PIN lesions (2 of 14 foci) showed TMPRSS2-ERG fusion type A. These PIN lesions with detectable TMPRSS2-ERG fusion may undergo further genetic changes to develop 
Conclusions
Information regarding the origin of multiple tumors in prostate cancer is critical to our understanding of the pathobiology and natural history of this disease. In this regard, prevalent oncogenic alterations of ERG due to TMPRSS2-ERG fusion in early-stage prostate cancer provide a break through observation to investigate the role of this potentially causal prostate cancer-specific genomic alteration in the origins of multi-focal prostate cancer. Our data show that half of the malignant areas in prostates harbor TMPRSS2-ERG fusions and apparent heterogeneity of TMPRSS2-ERG supports the independent origins of multi-focal tumors in the same prostate. Based on limited data, we suggest that foci of benign glands or PIN with TMPRSS2-ERG fusion type A may give rise to carcinoma. Thus, detection of benign glands with TMPRSS2-ERG fusion in biopsy or TURP specimen might suggest that these patients should be closely monitored.
